Literature DB >> 6768384

Human plasma prekallikrein. Studies of its activation by activated factor XII and of its inactivation by diisopropyl phosphofluoridate.

B N Bouma, L A Miles, G Beretta, J H Griffin.   

Abstract

Human plasma prekallikrein was purified from normal plasma. The purified prekallikrein appeared homogeneous on polyacrylamide gels in the presence of sodium dodecyl sulfate and mercaptoethanol and gave two protein bands with approximate Mr 85 000. Proteolytic activation of prekallikrein by purified human beta-factor XIIa (Mr 28 000 form) resulted in the formation of kallikrein. The apparent molecular weight of kallikrein determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis in the absence of mercaptoethanol was identical with that of prekallikrein; reduction of kallikrein yielded a heavy chain of Mr 52 000 and two light chains of Mr 42 000 and 37 000. The appearance of kallikrein activity was directly correlated with the limited proteolysis due to beta-factor XIIa. Kinetic and immunologic studies demonstrated that plasma prekallikrein is a factor XII dependent plasminogen proactivator. The rate constant for the inactivation of prekallikrein by diisopropyl phosphofluoridate was similar to that previously reported for trypsinogen. This observation raises the possibility that low intrinsinc catalytic activity of prekallikrein may play a role in the initiation of the intrinsic blood coagulation pathway.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6768384     DOI: 10.1021/bi00547a018

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  12 in total

Review 1.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

2.  Characterization of a variant prekallikrein, prekallikrein Long Beach, from a family with mixed cross-reacting material-positive and cross-reacting material-negative prekallikrein deficiency.

Authors:  B N Bouma; D M Kerbiriou; J Baker; J H Griffin
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

3.  Rapid purification of a high-affinity plasminogen activator from human blood plasma by specific adsorption on fibrin/Celite.

Authors:  S S Husain; B Lipinski; V Greuwich
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

4.  Blood coagulation factor XIa binds specifically to a site on activated human platelets distinct from that for factor XI.

Authors:  D Sinha; F S Seaman; A Koshy; L C Knight; P N Walsh
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

5.  Purification and characterization of two functionally distinct forms of C1 inhibitor from a patient with angioedema.

Authors:  J G Curd; M Yelvington; R J Ziccardi; D A Mathison; J H Griffin
Journal:  Clin Exp Immunol       Date:  1981-08       Impact factor: 4.330

6.  Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease.

Authors:  R A Marlar; J H Griffin
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

7.  The activation of the alternative pathway C3 convertase by human plasma kallikrein.

Authors:  R G DiScipio
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

8.  Human plasma kallikrein and C1 inhibitor form a complex possessing an epitope that is not detectable on the parent molecules: demonstration using a monoclonal antibody.

Authors:  A de Agostini; M Schapira; Y T Wachtfogel; R W Colman; S Carrel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

9.  Pathogenesis of periodontitis: a major arginine-specific cysteine proteinase from Porphyromonas gingivalis induces vascular permeability enhancement through activation of the kallikrein/kinin pathway.

Authors:  T Imamura; R N Pike; J Potempa; J Travis
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

10.  Amine prodrugs which utilize hydroxy amide lactonization. II. A potential esterase-sensitive amide prodrug.

Authors:  K L Amsberry; A E Gerstenberger; R T Borchardt
Journal:  Pharm Res       Date:  1991-04       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.